冠心病合并亚临床甲状腺功能减退的研究进展

张勋; 郑颖

doi:10.13201/j.issn.1001-1439.2024.06.005

冠心病合并亚临床甲状腺功能减退的研究进展

张勋^1,2,
郑颖^1,2, ,

- 1.
  天津中医药大学第一附属医院心血管科(天津，300381)
- 2.
  国家中医针灸临床医学研究中心

详细信息

通讯作者: 郑颖，E-mail：zy20062006@163.com

中图分类号: R541.4

收稿日期: 2023-06-12

刊出日期: 2024-06-13

Research progress in coronary heart disease complicated with subclinical hypothyroidism

ZHANG Xun^1,2,
ZHENG Ying^1,2, ,

- 1.
  Department of Cardiology, The First Affiliated Hospital of Tianjin University of Chinese Medicine, Tianjin, 300381, China
- 2.
  National Clinical Research Center for Acupuncture and Moxibustion of Traditional Chinese Medicine

More Information

Corresponding author: ZHENG Ying, E-mail: zy20062006@163.com

Received Date: 12 June 2023

Publish Date: 13 June 2024

摘要

摘要: 亚临床甲状腺功能减退症是一种比较常见的生化疾病，多项研究证实其可对心血管系统造成不利影响，并能加重冠心病患者的病情。本文通过检索近年来国内外相关研究文献，就亚临床甲状腺功能减退症对冠心病造成的主要影响、致病机制、相关因素及治疗手段等进行阐述，以期对该类疾病的诊治提供依据。
- 亚临床甲状腺功能减退 /
- 冠心病 /
- 心血管疾病
Abstract: Subclinical hypothyroidism is a relatively common biochemical disease that has been shown in multiple studies to adversely affect the cardiovascular system and aggravate the condition of patients with coronary atherosclerotic heart disease. By retrieving relevant research literature at home and abroad in the past 5 years, this paper focuses on the main impact, pathogenic mechanism, related factors and treatment methods of subclinical hypothyroidism on coronary heart disease, in order to provide effective reference opinions for the diagnosis and treatment of this disease.
- subclinical hypothyroidism /
- coronary heart disease /
- cardiovascular disease

HTML全文

参考文献(68)

[1]	Chaker L, Razvi S, Bensenor IM, et al. Hypothyroidism[J]. Nat Rev Dis Primers, 2022, 8(1): 30. doi: 10.1038/s41572-022-00357-7
[2]	Biondi B, Cappola AR, Cooper DS. Subclinical hypothyroidism: a review[J]. JAMA, 2019, 322(2): 153-160. doi: 10.1001/jama.2019.9052
[3]	中华医学会内分泌学分会. 成人甲状腺功能减退症诊治指南[J]. 中华内分泌代谢杂志, 2017, 20(2): 167-180. doi: 10.3760/cma.j.issn.1000-6699.2017.02.018
[4]	Moon S, Kim MJ, Yu JM, et al. Subclinical hypothyroidism and the risk of cardiovascular disease and all-cause mortality: a meta-analysis of prospective cohort studies[J]. Thyroid, 2018, 28(9): 1101-1110. doi: 10.1089/thy.2017.0414
[5]	van Vliet NA, Bos MM, Thesing CS, et al. Higher thyrotropin leads to unfavorable lipid profile and somewhat higher cardiovascular disease risk: evidence from multi-cohort Mendelian randomization and metabolomic profiling[J]. BMC Med, 2021, 19(1): 266. doi: 10.1186/s12916-021-02130-1
[6]	Fang H, Zhao R, Cui S, et al. Sex differences in major cardiovascular outcomes and fractures in patients with subclinical thyroid dysfunction: a systematic review and meta-analysis[J]. Aging, 2022, 14(20): 8448-8485.
[7]	Inoue K, Ritz B, Brent GA, et al. Association of subclinical hypothyroidism and cardiovascular disease with mortality[J]. JAMA Network Open, 2020, 3(2): e1920745. doi: 10.1001/jamanetworkopen.2019.20745
[8]	Han C, Xu K, Wang L, et al. Impact of persistent subclinical hypothyroidism on clinical outcomes in non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention[J]. Clin Endocrinol (Oxf), 2022, 96(1): 70-81. doi: 10.1111/cen.14613
[9]	梁彦, 张沛欣. 稳定性冠心病患者血清甲状腺激素水平与亚临床甲状腺功能减退症及冠状动脉侧支循环的关系研究[J]. 中国实验诊断学, 2018, 22(3): 385-389. doi: 10.3969/j.issn.1007-4287.2018.03.002
[10]	申泽雪, 李树仁, 郝潇, 等. 亚临床甲状腺功能减退症对非ST段抬高型心肌梗死患者心律失常事件的影响[J]. 中国循证心血管医学杂志, 2021, 13(2): 226-230. doi: 10.3969/j.issn.1674-4055.2021.02.24
[11]	Ang SP, Chia JE, Jaiswal V, et al. Subclinical hypothyroidism and clinical outcomes after percutaneous coronary intervention: a meta-analysis[J]. Curr Probl Cardiol, 2023, 48(8): 101719. doi: 10.1016/j.cpcardiol.2023.101719
[12]	周博通, 杨宏辉, 刘莹莹, 等. 亚临床甲状腺功能减退症对冠心病患者药物球囊介入治疗的影响[J]. 临床心血管病杂志, 2022, 38(9): 706-710. https://lcxxg.whuhzzs.com/article/doi/10.13201/j.issn.1001-1439.2022.09.005
[13]	Izkhakov E, Zahler D, Rozenfeld K, et al. Unknown subclinical hypothyroidism and in-hospital outcomes and short-and long-term all-cause mortality among ST segment elevation myocardial infarction patients undergoing percutaneous coronary intervention[J]. J Clin Med, 2020, 9(12): 3829. doi: 10.3390/jcm9123829
[14]	Liu YS, Wei M, Wang L, et al. The impact of subclinical hypothyroidism on long-term outcomes in older patients undergoing percutaneous coronary intervention[J]. BMC Endocr Disord, 2021, 21(1): 43. doi: 10.1186/s12902-021-00702-z
[15]	魏梅, 郭岐峰, 段立楠, 等. 亚临床甲状腺功能减退与老年病人经皮冠状动脉介入治疗术后死亡的相关性研究[J]. 实用老年医学, 2023, 37(2): 138-141. doi: 10.3969/j.issn.1003-9198.2023.02.008
[16]	Joe YE, Shin YR, Kwak YL, et al. Influence of mild thyroid dysfunction on outcomes after off-pump coronary artery bypass surgery[J]. J Clin Med, 2022, 11(17): 110.
[17]	Kim H, Kong SH, Moon JH, et al. Subclinical hypothyroidism affects the long-term outcomes of patients who undergo coronary artery bypass grafting surgery but not heart valve surgery[J]. Endocrinol Metab (Seoul), 2020, 35(2): 308-318. doi: 10.3803/EnM.2020.35.2.308
[18]	Kong SH, Yoon JW, Kim SY, et al. Subclinical hypothyroidism and coronary revascularization after coronary artery bypass grafting[J]. Am J Cardiol, 2018, 122(11): 1862-1870. doi: 10.1016/j.amjcard.2018.08.029
[19]	Chubb S, Peters KE, Bruce DG, et al. The relationship between thyroid dysfunction, cardiovascular morbidity and mortality in type 2 diabetes: The Fremantle Diabetes Study Phase Ⅱ[J]. Acta Diabetol, 2022, 59(12): 1615-1624. doi: 10.1007/s00592-022-01969-x
[20]	Zijlstra LE, van Velzen DM, Simsek S, et al. The kidney, subclinical thyroid disease and cardiovascular outcomes in older patients[J]. Endocr Connect, 2020, 9(1): 55-62. doi: 10.1530/EC-19-0502
[21]	Gluvic ZM, Zafirovic SS, Obradovic MM, et al. Hypothyroidism and risk of cardiovascular disease[J]. Curr Pharm Des, 2022, 28(25): 2065-2072. doi: 10.2174/1381612828666220620160516
[22]	Duntas LH, Brenta G. A renewed focus on the association between thyroid hormones and lipid metabolism[J]. Front Endocrinol(Lausanne), 2018, 9: 511. doi: 10.3389/fendo.2018.00511
[23]	Cai XQ, Tian F, Han TW, et al. Subclinical hypothyroidism is associated with lipid-rich plaques in patients with coronary artery disease as assessed by optical coherence tomography[J]. J Geriatr Cardiol, 2018, 15(8): 534-539.
[24]	李玲, 陈峰, 刘岩. 应用冠状动脉CT评估冠心病合并亚临床甲状腺功能减退病人的斑块特征[J]. 青岛大学学报(医学版), 2019, 55(6): 631-633, 638. https://www.cnki.com.cn/Article/CJFDTOTAL-BATE201906001.htm
[25]	Luo Y, Wu F, Huang Z, et al. Assessment of the relationship between subclinical hypothyroidism and blood lipid profile: reliable or not?[J]. Lipids Health Dis, 2022, 21(1): 137. doi: 10.1186/s12944-022-01749-0
[26]	中国高血压防治指南修订委员会, 中国高血压联盟, 中华医学会心血管病学分会, 等. 中国高血压防治指南(2018年修订版)[J]. 中国心血管杂志, 2019, 20(1): 24-56. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGGZ201904005.htm
[27]	Cai P, Peng Y, Chen Y, et al. Blood pressure characteristics of subclinical hypothyroidism: an observation study combined with office blood pressure and 24-h ambulatory blood pressure[J]. J Hypertens, 2021, 39(3): 453-460. doi: 10.1097/HJH.0000000000002655
[28]	Kim J, Prasitlumkum N, Randhawa S, et al. Association between subclinical hypothyroidism and incident hypertension in women: a systematic review and meta-analysis[J]. J Clin Med, 2021, 10(15): 110.
[29]	Boutouyrie P, Chowienczyk P, Humphrey JD, et al. Arterial stiffness and cardiovascular risk in hypertension[J]. Circ Res, 2021, 128(7): 864-886. doi: 10.1161/CIRCRESAHA.121.318061
[30]	Mousa S, Hemeda A, Ghorab H, et al. Arterial wall stiffness and the risk of atherosclerosis in egyptian patients with overt and subclinical hypothyroidism[J]. Endocrine Practice, 2020, 26(2): 161-166. doi: 10.4158/EP-2019-0322
[31]	白梦坡, 穆耶赛尔·麦麦提明, 刘惠娟, 等. 原发性高血压患者亚临床甲状腺功能减退与中心动脉压相关指标及脉搏波速度之间的关系[J]. 临床心血管病杂志, 2022, 38(4): 318-322. https://lcxxg.whuhzzs.com/article/doi/10.13201/j.issn.1001-1439.2022.04.013
[32]	Senoner T, Dichtl W. Oxidative stress in cardiovascular diseases: still a therapeutic target?[J]. Nutrients, 2019, 11(9): 110.
[33]	Unluturk U, Savas M, Oguz SH, et al. Oxysterol species generated by auto-oxidation in subclinical hypothyroidism[J]. Clin Biochem, 2021, 93: 73-79.
[34]	Libby P. Inflammation during the life cycle of the atherosclerotic plaque[J]. Cardiovasc Res, 2021, 117(13): 2525-2536.
[35]	Tellechea ML. Meta-analytic evidence for increased low-grade systemic inflammation and oxidative stress in hypothyroid patients. Can levothyroxine replacement therapy mitigate the burden?[J]. Endocrine, 2021, 72(1): 62-71.
[36]	Medina-Leyte DJ, Zepeda-García O, Domínguez-Pérez M, et al. Endothelial dysfunction, inflammation and coronary artery disease: potential biomarkers and promising therapeutical approaches[J]. Int J Mol Sci, 2021, 22(8): 110.
[37]	权晓慧, 王聪霞, 张春艳, 等. 冠心病合并亚临床甲减患者冠状动脉狭窄程度与内皮功能损伤的相关性[J]. 西安交通大学学报(医学版), 2018, 39(4): 471-474. https://www.cnki.com.cn/Article/CJFDTOTAL-XAYX201804006.htm
[38]	Beverly JK, Budoff MJ. Atherosclerosis: Pathophysiology of insulin resistance, hyperglycemia, hyperlipidemia, and inflammation[J]. J Diabetes, 2020, 12(2): 102-104.
[39]	Di Pino A, DeFronzo RA. Insulin resistance and atherosclerosis: implications for insulin-sensitizing agents[J]. Endocr Rev, 2019, 40(6): 1447-1467.
[40]	Park K, Li Q, Lynes MD, et al. Endothelial cells induced progenitors into brown fat to reduce atherosclerosis[J]. Circ Res, 2022, 131(2): 168-183.
[41]	Xu C, Zhou L, Wu K, et al. Abnormal glucose metabolism and insulin resistance are induced via the IRE1α/XBP-1 pathway in subclinical hypothyroidism[J]. Front Endocrinol (Lausanne), 2019, 10: 303.
[42]	Xu Q, Wang Y, Shen X, et al. The effect of subclinical hypothyroidism on coagulation and fibrinolysis: a systematic review and meta-analysis[J]. Front Endocrinol (Lausanne), 2022, 13: 861746.
[43]	Wang JJ, Zhuang ZH, Shao CL, et al. Assessment of causal association between thyroid function and lipid metabolism: a Mendelian randomization study[J]. Chin Med J (Engl), 2021, 134(9): 1064-1069.
[44]	Sun L, Xiao K, Miao Z, et al. Prognostic value of normal thyroid stimulating hormone in long-term mortality in patients with STEMI[J]. Front Endocrinol (Lausanne), 2022, 13: 806997.
[45]	Yang C, Lu M, Chen W, et al. Thyrotropin aggravates atherosclerosis by promoting macrophage inflammation in plaques[J]. J Exp Med, 2019, 216(5): 1182-1198.
[46]	Huang F, Wang K, Shen J. Lipoprotein-associated phospholipase A2: The story continues[J]. Med Res Rev, 2020, 40(1): 79-134.
[47]	Pantazi D, Tellis C, Tselepis AD. Oxidized phospholipids and lipoprotein-associated phospholipase A2 (Lp-PLA2) in atherosclerotic cardiovascular disease: An update[J]. Biofactors, 2022, 48(6): 1257-1270.
[48]	Xi H, Cheng GL, Hu FF, et al. The Use of lipoprotein-associated phospholipase A2 in a Chinese population to predict cardiovascular events[J]. Biomed Environ Sci, 2022, 35(3): 206-214.
[49]	王利娟, 杨旭明, 吴苑苑, 等. 冠心病患者亚临床甲状腺功能减退与血浆脂蛋白相关磷脂酶A2水平的相关性[J]. 中国心血管杂志, 2019, 24(6): 536-540. https://www.cnki.com.cn/Article/CJFDTOTAL-XIXG201906015.htm
[50]	Almeida González D, Rodríguez-Pérez M, Fuentes Ferrer M, et al. Irisin, in women and men: blood pressure, heart rate, obesity and insulin resistance[J]. Front Endocrinol (Lausanne), 2023, 14: 1193110.
[51]	Liu Q, Zhu Y, Li G, et al. Irisin ameliorates myocardial ischemia-reperfusion injury by modulating gut microbiota and intestinal permeability in rats[J]. PLoS One, 2023, 18(9): e291022.
[52]	Zhao YT, Wang J, Yano N, et al. Irisin promotes cardiac progenitor cell-induced myocardial repair and functional improvement in infarcted heart[J]. J Cell Physiol, 2019, 234(2): 1671-1681.
[53]	Alipoor E, Hosseinzadeh-Attar MJ, Vasheghani-Farahani A, et al. The relationship of circulating neuregulin 4 and irisin, and traditional and novel cardiometabolic risk factors with the risk and severity of coronary artery disease[J]. Cytokine, 2023, 170: 156314.
[54]	Stratigou T, Dalamaga M, Antonakos G, et al. Hyperirisinemia is independently associated with subclinical hypothyroidism: correlations with cardiometabolic biomarkers and risk factors[J]. Endocrine, 2018, 61(1): 83-93.
[55]	Farkhondeh T, Llorens S, Pourbagher-Shahri AM, et al. An overview of the role of adipokines in cardiometabolic diseases[J]. Molecules, 2020, 25(21): 110.
[56]	Zhang KZ, Shen XY, Wang M, et al. Retinol-binding protein 4 promotes cardiac injury after myocardial infarction via inducing cardiomyocyte pyroptosis through an interaction with NLRP3[J]. J Am Heart Assoc, 2021, 10(22): e22011.
[57]	Sun HX, Ji HH, Chen XL, et al. Serum retinol-binding protein 4 is associated with the presence and severity of coronary artery disease in patients with subclinical hypothyroidism[J]. Aging(Albany NY), 2019, 11(13): 4510-4520.
[58]	柴晏, 赵玉青, 郭旭男, 等. 冠状动脉粥样硬化性心脏病患者心外膜脂肪组织的生物信息学研究[J]. 中国全科医学, 2023, 26(8): 939-950. https://www.cnki.com.cn/Article/CJFDTOTAL-QKYX202308006.htm
[59]	谢杨, 石波, 刘家开, 等. 亚临床甲状腺功能减退症患者血清TSH水平与心外膜脂肪厚度的关系[J]. 郑州大学学报(医学版), 2022, 57(6): 858-861. https://www.cnki.com.cn/Article/CJFDTOTAL-HNYK202206025.htm
[60]	Closs C, Vargas-Uricoechea H, Schwarzstein D, et al. Relationship of subclinical hypothyroidism on epicardial adipose tissue: a systematic review and meta-analysis[J]. Curr Probl Cardiol, 2023, 48(7): 101674.
[61]	Farghaly HS, Metwalley KA, Raafat DM, et al. Epicardial fat thickness in children with subclinical hypothyroidism and its relationship to subclinical atherosclerosis: a pilot study[J]. Horm Res Paediatr, 2019, 92(2): 99-105.
[62]	Wilson SA, Stem LA, Bruehlman RD. Hypothyroidism: diagnosis and treatment[J]. Am Fam Physician, 2021, 103(10): 605-613.
[63]	母雪飞, 李毅, 王贺阳, 等. 左旋甲状腺激素片在急性冠脉综合征合并亚临床甲状腺功能减退中应用临床研究[J]. 临床军医杂志, 2018, 46(5): 531-533. https://www.cnki.com.cn/Article/CJFDTOTAL-JYGZ201805008.htm
[64]	Jabbar A, Ingoe L, Junejo S, et al. Effect of levothyroxine on left ventricular ejection fraction in patients with subclinical hypothyroidism and acute myocardial infarction: a randomized clinical trial[J]. JAMA, 2020, 324(3): 249-258.
[65]	Stott DJ, Rodondi N, Kearney PM, et al. Thyroid hormone therapy for older adults with subclinical hypothyroidism[J]. N Engl J Med, 2017, 376(26): 2534-2544.
[66]	Mooijaart SP, Du Puy RS, Stott DJ, et al. Association between levothyroxine treatment and thyroid-related symptoms among adults aged 80 years and older with subclinical hypothyroidism[J]. JAMA, 2019, 322(20): 1977-1986.
[67]	Cappola AR. The thyrotropin reference range should be changed in older patients[J]. JAMA, 2019, 322(20): 1961-1962.
[68]	Biondi B, Cappola AR. Subclinical hypothyroidism in older individuals[J]. Lancet Diabetes Endocrinol, 2022, 10(2): 129-141.